Axsome Executive Sells $2.3M in Stock Through Multiple Transactions

Form 144 Notice filed by Axsome Therapeutics (NASDAQ: AXSM) on June 28, 2025, detailing proposed securities sales under Rule 144.

Rhea-AI Filing Summary

Form 144 Notice filed by Axsome Therapeutics (NASDAQ: AXSM) on June 28, 2025, detailing proposed securities sales under Rule 144. The filing indicates planned sale of 7,500 shares of common stock with an aggregate market value of $768,503 through Charles Schwab & Co.

Key transaction details:

• Securities acquired through employee stock option exercise on June 20, 2025
• Payment made via broker payment for cashless exercise
• Total shares outstanding: 49,236,365
• Planned sale date: June 20, 2025

The filing also discloses previous sales by Hunter R. Murdock in the past 3 months totaling 22,500 shares across three transactions from June 16-18, 2025, with gross proceeds ranging from $751,975 to $768,154. The seller represents no knowledge of undisclosed material adverse information regarding the issuer.

Positive

• None.

Negative

• Insider Hunter R. Murdock has sold a total of 22,500 shares over three consecutive days (June 16-18, 2025) for approximately $2.28M, followed by another planned sale of 7,500 shares, indicating consistent selling pressure from management

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AXSM shares were sold by Hunter R. Murdock in June 2025?

According to the Form 144 filing, Hunter R. Murdock sold three batches of 7,500 shares each on June 16, 17, and 18, 2025, totaling 22,500 shares. Additionally, there is a proposed sale of another 7,500 shares with an approximate sale date of June 20, 2025.

What was the total value of AXSM shares sold by Hunter Murdock in mid-June 2025?

The total gross proceeds from Hunter Murdock's sales were: $768,154 (June 16), $751,975 (June 17), and $756,729 (June 18), totaling $2,276,858 for the three transactions.

How did Hunter Murdock acquire the AXSM shares being sold?

The Form 144 indicates that the shares were acquired through an Employee Stock Option Exercise on June 20, 2025, with payment made through a Broker Payment for Cashless Exercise.

What is the total number of outstanding AXSM shares according to the June 2025 Form 144?

According to the Form 144 filing, Axsome Therapeutics had 49,236,365 shares outstanding at the time of the filing.

Through which broker is Hunter Murdock selling AXSM shares?

The shares are being sold through Charles Schwab & Co., Inc., located at 3000 Schwab Way, Westlake TX 76262.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/20/2025 - 04:08 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001934008
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Axsome Therapeutics, Inc.
SEC File Number	001-37635
Address of Issuer	ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NEW YORK 10007
Phone	(212) 332-3241
Name of Person for Whose Account the Securities are To Be Sold	Murdock Hunter R.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	7500	768503.00	49236365	06/20/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/20/2025	Employee Stock Option Exercise	Axsome Therapeutics, Inc.			7500	06/20/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Hunter R. Murdock ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	06/16/2025	7500	768154.00
Hunter R. Murdock ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	06/17/2025	7500	751975.00
Hunter R. Murdock ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	06/18/2025	7500	756729.00

144: Remarks and Signature

Remarks
Date of Notice	06/20/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/04/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Hunter R. Murdock
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)